Biogen Spinraza Treatment Delays Show COVID-19 Is Already Impacting Hospital Treatments
Biogen confirmed that some patients treated with Spinraza are temporarily having their dosing postponed as hospital systems brace for COVID-19, potentially a broader issue for the industry.
You may also be interested in...
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
With top-line data showing efficacy in type 1 SMA patients, risdiplam may be able to obtain a label that would address significantly more patients than Novartis’ Zolgensma. Final efficacy data will show how drug’s efficacy compares to Biogen’s Spinraza.
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.